Zinc supplementation stimulates tetanus antibody formation and soluble interleukin-2 receptor levels in chronic hemodialysis patients
- PMID: 8374246
- DOI: 10.1007/BF00208476
Zinc supplementation stimulates tetanus antibody formation and soluble interleukin-2 receptor levels in chronic hemodialysis patients
Abstract
Immunodepression in end-stage renal disease has been associated with zinc deficiency. In a controlled study serum zinc levels, serum concentrations of soluble interleukin-2 receptor (sIL-2R), and tetanus IgG antibody titers were measured in 65 hemodialysis patients before and after intravenous zinc supplementation for 2 months. The hemodialysis patients had significantly lower predialysis serum zinc concentrations compared to healthy controls (63 +/- 1.65 versus 126 +/- 4.6 micrograms/dl, P < 0.001). Serum zinc concentrations increased to the normal range in the zinc-treated patients. After zinc substitution tetanus antibody titers rose significantly (0.81 +/- 0.12 versus 1.22 +/- 0.12 U/ml, P < 0.01). Pretreatment sIL-2R levels were elevated in 95% of examined patients. A further increase in sIL-2R was observed after zinc supplementation (234 +/- 14 versus 285 +/- 21 U/ml, P < 0.05). The results suggest that zinc induces the activation of T lymphocytes and T-cell dependent B lymphocytes in chronic uremic patients in vivo.
Similar articles
-
Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin.Blood Purif. 1995 Nov-Dec;13(6):347-56. doi: 10.1159/000170219. Blood Purif. 1995. PMID: 8821199
-
[Effect of zinc substitution on lymphocyte subsets and cellular immune function in hemodialysis patients].Klin Wochenschr. 1991 Jun 18;69(9):392-6. doi: 10.1007/BF01647412. Klin Wochenschr. 1991. PMID: 1921241 Clinical Trial. German.
-
Evidence of mononuclear cell activation by hemodialysis.ASAIO Trans. 1991 Jul-Sep;37(3):M386-7. ASAIO Trans. 1991. PMID: 1751200
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Immune deficiency of the uremic patient.Adv Nephrol Necker Hosp. 1990;19:259-74. Adv Nephrol Necker Hosp. 1990. PMID: 2105582 Review. No abstract available.
Cited by
-
The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis.Ren Fail. 2020 Nov;42(1):419-427. doi: 10.1080/0886022X.2020.1761388. Ren Fail. 2020. PMID: 32401100 Free PMC article.
-
Trace elements in hemodialysis patients: a systematic review and meta-analysis.BMC Med. 2009 May 19;7:25. doi: 10.1186/1741-7015-7-25. BMC Med. 2009. PMID: 19454005 Free PMC article.
-
Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.Int J Clin Oncol. 2019 Sep;24(9):1151-1160. doi: 10.1007/s10147-019-01455-5. Epub 2019 Jun 10. Int J Clin Oncol. 2019. PMID: 31183777
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical